ARHGDIA-RNF213 Fusion FISH Probe
The ARHGDIA-RNF213 Fusion FISH Probe is used to confirm a fusion of the ARHGDIA and RNF213 genes. The fusion of the ARHGDIA and RNF213 genes has been associated with Lung Adenocarcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| ARHGDIA-RNF213-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-RERE | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-REOR | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-REGO | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-REGR | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-OROR | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-GORE | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-GROR | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| ARHGDIA-RNF213-20-AQAQ | 20 (40 μL) | 200 μL |
|
ARHGDIA Gene Summary
This gene encodes a protein that plays a key role in the regulation of signaling through Rho GTPases. The encoded protein inhibits the disassociation of Rho family members from GDP (guanine diphosphate), thereby maintaining these factors in an inactive state. Activity of this protein is important in a variety of cellular processes, and expression of this gene may be altered in tumors. Mutations in this gene have been found in individuals with nephrotic syndrome, type 8. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Jul 2014]
Gene Name: Rho GDP Dissociation Inhibitor Alpha
Chromosome: CHR17: 79825596 -79829282
Locus: 17q25.3
RNF213 Gene Summary
This gene encodes a protein containing a C3HC4-type RING finger domain, which is a specialized type of Zn-finger that binds two atoms of zinc and is thought to be involved in mediating protein-protein interactions. The protein also contains an AAA domain, which is associated with ATPase activity. This gene is a susceptibility gene for Moyamoya disease, a vascular disorder of intracranial arteries. This gene is also a translocation partner in anaplastic large cell lymphoma and inflammatory myofibroblastic tumor cases, where a t(2;17)(p23;q25) translocation has been identified with the anaplastic lymphoma kinase (ALK) gene on chromosome 2, and a t(8;17)(q24;q25) translocation has been identified with the MYC gene on chromosome 8. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2011]
Gene Name: Ring Finger Protein 213
Chromosome: CHR17: 78234666 -78370086
Locus: 17q25.3
Gene Diseases
The ARHGDIA RNF213 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Lung Adenocarcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|